{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:57:29Z","timestamp":1793969849765,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.lungcan.2024.107535","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:01:20Z","timestamp":1710460880000},"page":"107535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["A pragmatic guide for management of adverse events associated with lorlatinib"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-7296","authenticated-orcid":false,"given":"Geoffrey","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-7613","authenticated-orcid":false,"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-6622","authenticated-orcid":false,"given":"Jan","family":"Stratmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3078-5043","authenticated-orcid":false,"given":"Mary","family":"Grizzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.107535_b0005","unstructured":"American Cancer Society, Lung cancer early detection, diagnosis, and staging. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging.html (accessed 20 July 2023)."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107535_b0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hoc.2016.08.012","article-title":"Diagnosis and treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"31","author":"Arbour","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107535_b0020","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.21037\/jtd-23-380","article-title":"A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer","volume":"15","author":"Wang","year":"2023","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107535_b0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0030","first-page":"13","article-title":"Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.lungcan.2024.107535_b0040","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107535_b0045","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107535_b0050","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2024.107535_b0055","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107535_b0060","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2024.107535_b0065","unstructured":"Pfizer, Lorbrena (lorlatinib) prescribing information. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11140 (accessed 20 July 2023)."},{"key":"10.1016\/j.lungcan.2024.107535_b0070","unstructured":"European Medicines Agency, Lorviqua summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lorviqua-epar-product-information_en.pdf (accessed 20 July 2023)."},{"key":"10.1016\/j.lungcan.2024.107535_b0075","unstructured":"Health Canada, Lorbrena product monograph including patient medication information. https:\/\/pdf.hres.ca\/dpd_pm\/00061480.PDF (accessed 20 July 2023)."},{"key":"10.1016\/j.lungcan.2024.107535_b0080","unstructured":"Australian Therapeutic Goods Administration, Lorviqua. https:\/\/www.tga.gov.au\/resources\/auspmd\/lorviqua (accessed 20 July 2023)."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107535_b0085","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1111\/cas.14576","article-title":"Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study","volume":"111","author":"Seto","year":"2020","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107535_b0090","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtho.2022.09.219","article-title":"Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies","volume":"18","author":"Dagogo-Jack","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107535_b0100","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107535_b0105","doi-asserted-by":"crossref","unstructured":"D.R. Camidge, H.R. Kim, M.J. Ahn, J.C.H. Yang, J.Y. Han, M.J. Hochmair, K.H. Lee, A. Delmonte, M.R. Garcia Campelo, D.W. Kim, F. Griesinger, E. Felip, R. Califano, A.I. Spira, S.N. Gettinger, M. Tiseo, H.M. Lin, Y. Liu, F. Vranceanu, H. Niu, P. Zhang, S. Popat, Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial, J. Thorac. Oncol. 16 (12) (2021) 2091\u20132108, https:\/\/doi.org\/10.1016\/j.jtho.2021.07.035.","DOI":"10.1016\/j.jtho.2021.07.035"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107535_b0110","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jtho.2020.04.019","article-title":"An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor-refractory ALK-positive or ROS1-positive NSCLC","volume":"15","author":"Zhu","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107535_b0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2020.07.022","article-title":"GLASS: global lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients","volume":"148","author":"Peled","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107535_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2023.12.019","article-title":"Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer","author":"Shih","year":"2024","journal-title":"J. Formos. Med. Assoc."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107535_b0125","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/CAD.0000000000001107","article-title":"Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients","volume":"32","author":"Lee","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2024.107535_b0130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2022.11.004","article-title":"Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer","volume":"174","author":"Mazieres","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107535_b0135","doi-asserted-by":"crossref","unstructured":"B.J. Solomon, T.M. Bauer, S.H. Ignatius Ou, G. Liu, H. Hayashi, A. Bearz, K. Penkov, Y.L. Wu, O. Arrieta, J. Jassem, A.M. Calella, G. Peltz, A. Polli, H. Thurm, T. Mok, Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study, J. Clin. Oncol. 40 (31) (2022) 3593\u20133602, https:\/\/doi.org\/10.1200\/JCO.21.02278.","DOI":"10.1200\/JCO.21.02278"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107535_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101560","article-title":"Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors","volume":"8","author":"Zhou","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2024.107535_b0145","doi-asserted-by":"crossref","unstructured":"A. Bearz, E. Felip, J. Mazieres, F. de Marinis, T. Bauer, A. Polli, R. Messina, H. Thurm, D. Thomaidou, T.S.K. Mok, B.J. Solomon, 979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study, Ann. Oncol. 33 S998-S999, https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1107.","DOI":"10.1016\/j.annonc.2022.07.1107"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107535_b0150","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40264-021-01083-x","article-title":"Monitoring and managing lorlatinib adverse events in the Portuguese clinical setting: a position paper","volume":"44","author":"Barata","year":"2021","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107535_b0155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12325-019-01198-9","article-title":"The effect of rifampin on the pharmacokinetics and safety of lorlatinib: results of a phase one, open-label, crossover study in healthy participants","volume":"37","author":"Chen","year":"2020","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107535_b0160","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107535_b0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0170","first-page":"28","article-title":"Alirocumab (Praluent): first in the new class of PCSK9 inhibitors","volume":"41","author":"Manniello","year":"2016","journal-title":"Pharm. Therap."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107535_b0175","doi-asserted-by":"crossref","first-page":"EE176-E178","DOI":"10.1016\/j.cllc.2023.03.016","article-title":"The efficacy of PCSK9 inhibitors in treating hypercholesterolemia caused by lorlatinib: a report of two cases","volume":"24","author":"Khairunnisa","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107535_b0180","doi-asserted-by":"crossref","first-page":"4721357","DOI":"10.1155\/2018\/4721357","article-title":"Management of hypertriglyceridemia induced acute pancreatitis","volume":"2018","author":"Garg","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107535_b0185","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/2050640618755002","article-title":"Hypertriglyceridemic pancreatitis: epidemiology, pathophysiology and clinical management","volume":"6","author":"de Pretis","year":"2018","journal-title":"United European Gastroenterol. J."},{"key":"10.1016\/j.lungcan.2024.107535_b0190","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 21 February 2023)."},{"key":"10.1016\/j.lungcan.2024.107535_b0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1741-7015-11-83","article-title":"Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis","volume":"11","author":"Aramapatzis","year":"2013","journal-title":"BMC Med."},{"issue":"1149","key":"10.1016\/j.lungcan.2024.107535_b0200","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med. J."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107535_b0205","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2023.03.020","article-title":"Analysis of serious weight gain in patients using alectinib for ALK-positive lung cancer","volume":"18","author":"de Leeuw","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107535_b0210","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.14373","article-title":"Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Dahl","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MED.0000000000000448","article-title":"Gastrointestinal hormones and regulation of gastric emptying","volume":"26","author":"Camilleri","year":"2019","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"23","key":"10.1016\/j.lungcan.2024.107535_b0220","article-title":"In-depth analysis of lorlatinib-related neurocognitive adverse events in patients with non-small-cell lung cancer","author":"Schoenmaekers","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107535_b0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","article-title":"NCCN guidelines insights: antiemesis, version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107535_b0230","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-related fatigue, version 2.2015: clinical practice guidelines in oncology","volume":"13","author":"Berger","year":"2015","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107535_b0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/curroncol28010029","article-title":"Evaluation and management of dyslipidemia in patients treated with lorlatinib","volume":"28","author":"Blais","year":"2021","journal-title":"Curr. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T18:32:56Z","timestamp":1715625176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":47,"alternative-id":["S0169500224000680"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107535","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pragmatic guide for management of adverse events associated with lorlatinib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107535"}}